Chinese- REPORT SUMMARY
- TABLE OF CONTENTS
-
Parkinson's Disease (PD) Drugs market report explains the definition, types, applications, major countries, and major players of the Parkinson's Disease (PD) Drugs market. The report mainly contains different types, applications, and regional historical data from 2017-2021 and forecast data from 2022-2028.
The report contains qualitative and quantitative analysis of the entire industry.
The influence of COVID-19 has been considered in the report. Coronavirus Impact is included in Chapter 2. In addition, Strategic Analytics to Boost Productivity and Profitability is included in Chapter 3.
By Player:
AbbVie
Pfizer
Otsuka Pharmaceutical
Biogen
F Hoffmann-La Roche
Kyowa Hakko Kirin
Impax Laboratories
Novartis
Addex Therapeutics
Abital Pharma
GlaxoSmithKline
Eli Lilly
Boehringer Ingelheim
Teva Pharmaceutical Industries
Eisai
H Lundbeck
By Type:
Dopamine Agonist
Monoamine Oxidase Inhibitors
Acetylcholinesterase Inhibitors
Glutamate Inhibitors
By End-User:
Hospital
Family
By Region:
North America
-
United States
-
Canada
-
Mexico
Europe
-
Germany
-
UK
-
Spain
-
France
-
Italy
-
Denmark
-
Finland
-
Norway
-
Sweden
-
Poland
-
Russia
-
Turkey
Asia-Pacific
-
China
-
Japan
-
India
-
South Korea
-
Pakistan
-
Bangladesh
-
Indonesia
-
Thailand
-
Singapore
-
Malaysia
-
Philippines
-
Vietnam
-
Others
South America
-
Brazil
-
Colombia
-
Chile
-
Argentina
-
Venezuela
-
Peru
-
Puerto Rico
-
Ecuador
-
Others
GCC
-
Bahrain
-
Kuwait
-
Oman
-
Qatar
-
Saudi Arabia
-
United Arab Emirates
Africa
-
Nigeria
-
South Africa
-
Egypt
-
Algeriat
-
Others
Oceania
-
Australia
-
New Zealand
TABLE OF CONTENT
1. Global Parkinson's Disease (PD) Drugs Executive Summary
-
1.1 Introduction
-
1.2 Market Panorama, 2022
2 Coronavirus Impact
-
2.1 Parkinson's Disease (PD) Drugs Outlook to 2028- Original Forecasts
-
2.2 Parkinson's Disease (PD) Drugs Outlook to 2028- COVID-19 Affected Forecasts
-
2.3 Impact on Industry
3 Strategic Analytics to Boost Productivity and Profitability
-
3.1 Potential Market Drivers and Opportunities
-
3.2 New Challenges and Strategies
-
3.3 Short Term and Long Term Parkinson's Disease (PD) Drugs Market Trends
4 Key Inferences
5 Market Overview
-
5.1 Current Market Scenario
-
5.2 Porter's Five Forces Analysis
-
5.2.1 Bargaining Power of Suppliers
-
5.2.2 Bargaining Power of Consumers
-
5.2.3 Threat of New Entrants
-
5.2.4 Threat of Substitute Product and Services
-
5.2.5 Competitive Rivalry within the Industry
6 Global Parkinson's Disease (PD) Drugs Market- Recent Developments
-
6.1 Parkinson's Disease (PD) Drugs Market News and Developments
-
6.2 Parkinson's Disease (PD) Drugs Market Deals Landscape
7 Parkinson's Disease (PD) Drugs Raw Materials and Cost Structure Analysis
-
7.1 Parkinson's Disease (PD) Drugs Key Raw Materials
-
7.2 Parkinson's Disease (PD) Drugs Price Trend of Key Raw Materials
-
7.3 Parkinson's Disease (PD) Drugs Key Suppliers of Raw Materials
-
7.4 Parkinson's Disease (PD) Drugs Market Concentration Rate of Raw Materials
-
7.5 Parkinson's Disease (PD) Drugs Cost Structure Analysis
-
7.5.1 Parkinson's Disease (PD) Drugs Raw Materials Analysis
-
7.5.2 Parkinson's Disease (PD) Drugs Labor Cost Analysis
-
7.5.3 Parkinson's Disease (PD) Drugs Manufacturing Expenses Analysis
8 Global Parkinson's Disease (PD) Drugs Import and Export Analysis (Top 10 Countries)
-
8.1 Global Parkinson's Disease (PD) Drugs Import by Region (Top 10 Countries) (2017-2028)
-
8.2 Global Parkinson's Disease (PD) Drugs Export by Region (Top 10 Countries) (2017-2028)
9 Global Parkinson's Disease (PD) Drugs Market Outlook by Types and Applications to 2022
-
9.1 Global Parkinson's Disease (PD) Drugs Consumption and Growth Rate by Type (2017-2022)
-
9.1.1 Global Dopamine Agonist Consumption and Growth Rate (2017-2022)
-
9.1.2 Global Monoamine Oxidase Inhibitors Consumption and Growth Rate (2017-2022)
-
9.1.3 Global Acetylcholinesterase Inhibitors Consumption and Growth Rate (2017-2022)
-
9.1.4 Global Glutamate Inhibitors Consumption and Growth Rate (2017-2022)
-
9.2 Global Parkinson's Disease (PD) Drugs Consumption and Growth Rate by Application (2017-2022)
-
9.2.1 Global Hospital Consumption and Growth Rate (2017-2022)
-
9.2.2 Global Family Consumption and Growth Rate (2017-2022)
10 Region and Country-wise Parkinson's Disease (PD) Drugs Market Analysis and Outlook till 2022
-
10.1 Global Parkinson's Disease (PD) Drugs Consumption (2017-2022)
-
10.2 North America Consumption Analysis
-
10.2.1 United States Parkinson's Disease (PD) Drugs Consumption (2017-2022)
-
10.2.2 Canada Parkinson's Disease (PD) Drugs Consumption (2017-2022)
-
10.2.3 Mexico Parkinson's Disease (PD) Drugs Consumption (2017-2022)
-
10.3 Europe Consumption Analysis
-
10.3.1 Germany Parkinson's Disease (PD) Drugs Consumption (2017-2022)
-
10.3.2 UK Parkinson's Disease (PD) Drugs Consumption (2017-2022)
-
10.3.3 Spain Parkinson's Disease (PD) Drugs Consumption (2017-2022)
-
10.3.4 Belgium Parkinson's Disease (PD) Drugs Consumption (2017-2022)
-
10.3.5 France Parkinson's Disease (PD) Drugs Consumption (2017-2022)
-
10.3.6 Italy Parkinson's Disease (PD) Drugs Consumption (2017-2022)
-
10.3.7 Denmark Parkinson's Disease (PD) Drugs Consumption (2017-2022)
-
10.3.8 Finland Parkinson's Disease (PD) Drugs Consumption (2017-2022)
-
10.3.9 Norway Parkinson's Disease (PD) Drugs Consumption (2017-2022)
-
10.3.10 Sweden Parkinson's Disease (PD) Drugs Consumption (2017-2022)
-
10.3.11 Poland Parkinson's Disease (PD) Drugs Consumption (2017-2022)
-
10.3.12 Russia Parkinson's Disease (PD) Drugs Consumption (2017-2022)
-
10.3.13 Turkey Parkinson's Disease (PD) Drugs Consumption (2017-2022)
-
10.4 APAC Consumption Analysis
-
10.4.1 China Parkinson's Disease (PD) Drugs Consumption (2017-2022)
-
10.4.2 Japan Parkinson's Disease (PD) Drugs Consumption (2017-2022)
-
10.4.3 India Parkinson's Disease (PD) Drugs Consumption (2017-2022)
-
10.4.4 South Korea Parkinson's Disease (PD) Drugs Consumption (2017-2022)
-
10.4.5 Pakistan Parkinson's Disease (PD) Drugs Consumption (2017-2022)
-
10.4.6 Bangladesh Parkinson's Disease (PD) Drugs Consumption (2017-2022)
-
10.4.7 Indonesia Parkinson's Disease (PD) Drugs Consumption (2017-2022)
-
10.4.8 Thailand Parkinson's Disease (PD) Drugs Consumption (2017-2022)
-
10.4.9 Singapore Parkinson's Disease (PD) Drugs Consumption (2017-2022)
-
10.4.10 Malaysia Parkinson's Disease (PD) Drugs Consumption (2017-2022)
-
10.4.11 Philippines Parkinson's Disease (PD) Drugs Consumption (2017-2022)
-
10.4.12 Vietnam Parkinson's Disease (PD) Drugs Consumption (2017-2022)
-
10.5 South America Consumption Analysis
-
10.5.1 Brazil Parkinson's Disease (PD) Drugs Consumption (2017-2022)
-
10.5.2 Colombia Parkinson's Disease (PD) Drugs Consumption (2017-2022)
-
10.5.3 Chile Parkinson's Disease (PD) Drugs Consumption (2017-2022)
-
10.5.4 Argentina Parkinson's Disease (PD) Drugs Consumption (2017-2022)
-
10.5.5 Venezuela Parkinson's Disease (PD) Drugs Consumption (2017-2022)
-
10.5.6 Peru Parkinson's Disease (PD) Drugs Consumption (2017-2022)
-
10.5.7 Puerto Rico Parkinson's Disease (PD) Drugs Consumption (2017-2022)
-
10.5.8 Ecuador Parkinson's Disease (PD) Drugs Consumption (2017-2022)
-
10.6 GCC Consumption Analysis
-
10.6.1 Bahrain Parkinson's Disease (PD) Drugs Consumption (2017-2022)
-
10.6.2 Kuwait Parkinson's Disease (PD) Drugs Consumption (2017-2022)
-
10.6.3 Oman Parkinson's Disease (PD) Drugs Consumption (2017-2022)
-
10.6.4 Qatar Parkinson's Disease (PD) Drugs Consumption (2017-2022)
-
10.6.5 Saudi Arabia Parkinson's Disease (PD) Drugs Consumption (2017-2022)
-
10.6.6 United Arab Emirates Parkinson's Disease (PD) Drugs Consumption (2017-2022)
-
10.7 Africa Consumption Analysis
-
10.7.1 Nigeria Parkinson's Disease (PD) Drugs Consumption (2017-2022)
-
10.7.2 South Africa Parkinson's Disease (PD) Drugs Consumption (2017-2022)
-
10.7.3 Egypt Parkinson's Disease (PD) Drugs Consumption (2017-2022)
-
10.7.4 Algeria Parkinson's Disease (PD) Drugs Consumption (2017-2022)
-
10.8 Oceania Consumption Analysis
-
10.8.1 Australia Parkinson's Disease (PD) Drugs Consumption (2017-2022)
-
10.8.2 New Zealand Parkinson's Disease (PD) Drugs Consumption (2017-2022)
11 Global Parkinson's Disease (PD) Drugs Competitive Analysis
-
11.1 AbbVie
-
11.1.1 AbbVie Company Details
-
11.1.2 AbbVie Parkinson's Disease (PD) Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
11.1.3 AbbVie Parkinson's Disease (PD) Drugs Main Business and Markets Served
-
11.1.4 AbbVie Parkinson's Disease (PD) Drugs Product Portfolio
-
11.1.5 Recent Research and Development Strategies
-
11.2 Pfizer
-
11.2.1 Pfizer Company Details
-
11.2.2 Pfizer Parkinson's Disease (PD) Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
11.2.3 Pfizer Parkinson's Disease (PD) Drugs Main Business and Markets Served
-
11.2.4 Pfizer Parkinson's Disease (PD) Drugs Product Portfolio
-
11.2.5 Recent Research and Development Strategies
-
11.3 Otsuka Pharmaceutical
-
11.3.1 Otsuka Pharmaceutical Company Details
-
11.3.2 Otsuka Pharmaceutical Parkinson's Disease (PD) Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
11.3.3 Otsuka Pharmaceutical Parkinson's Disease (PD) Drugs Main Business and Markets Served
-
11.3.4 Otsuka Pharmaceutical Parkinson's Disease (PD) Drugs Product Portfolio
-
11.3.5 Recent Research and Development Strategies
-
11.4 Biogen
-
11.4.1 Biogen Company Details
-
11.4.2 Biogen Parkinson's Disease (PD) Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
11.4.3 Biogen Parkinson's Disease (PD) Drugs Main Business and Markets Served
-
11.4.4 Biogen Parkinson's Disease (PD) Drugs Product Portfolio
-
11.4.5 Recent Research and Development Strategies
-
11.5 F Hoffmann-La Roche
-
11.5.1 F Hoffmann-La Roche Company Details
-
11.5.2 F Hoffmann-La Roche Parkinson's Disease (PD) Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
11.5.3 F Hoffmann-La Roche Parkinson's Disease (PD) Drugs Main Business and Markets Served
-
11.5.4 F Hoffmann-La Roche Parkinson's Disease (PD) Drugs Product Portfolio
-
11.5.5 Recent Research and Development Strategies
-
11.6 Kyowa Hakko Kirin
-
11.6.1 Kyowa Hakko Kirin Company Details
-
11.6.2 Kyowa Hakko Kirin Parkinson's Disease (PD) Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
11.6.3 Kyowa Hakko Kirin Parkinson's Disease (PD) Drugs Main Business and Markets Served
-
11.6.4 Kyowa Hakko Kirin Parkinson's Disease (PD) Drugs Product Portfolio
-
11.6.5 Recent Research and Development Strategies
-
11.7 Impax Laboratories
-
11.7.1 Impax Laboratories Company Details
-
11.7.2 Impax Laboratories Parkinson's Disease (PD) Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
11.7.3 Impax Laboratories Parkinson's Disease (PD) Drugs Main Business and Markets Served
-
11.7.4 Impax Laboratories Parkinson's Disease (PD) Drugs Product Portfolio
-
11.7.5 Recent Research and Development Strategies
-
11.8 Novartis
-
11.8.1 Novartis Company Details
-
11.8.2 Novartis Parkinson's Disease (PD) Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
11.8.3 Novartis Parkinson's Disease (PD) Drugs Main Business and Markets Served
-
11.8.4 Novartis Parkinson's Disease (PD) Drugs Product Portfolio
-
11.8.5 Recent Research and Development Strategies
-
11.9 Addex Therapeutics
-
11.9.1 Addex Therapeutics Company Details
-
11.9.2 Addex Therapeutics Parkinson's Disease (PD) Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
11.9.3 Addex Therapeutics Parkinson's Disease (PD) Drugs Main Business and Markets Served
-
11.9.4 Addex Therapeutics Parkinson's Disease (PD) Drugs Product Portfolio
-
11.9.5 Recent Research and Development Strategies
-
11.10 Abital Pharma
-
11.10.1 Abital Pharma Company Details
-
11.10.2 Abital Pharma Parkinson's Disease (PD) Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
11.10.3 Abital Pharma Parkinson's Disease (PD) Drugs Main Business and Markets Served
-
11.10.4 Abital Pharma Parkinson's Disease (PD) Drugs Product Portfolio
-
11.10.5 Recent Research and Development Strategies
-
11.11 GlaxoSmithKline
-
11.11.1 GlaxoSmithKline Company Details
-
11.11.2 GlaxoSmithKline Parkinson's Disease (PD) Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
11.11.3 GlaxoSmithKline Parkinson's Disease (PD) Drugs Main Business and Markets Served
-
11.11.4 GlaxoSmithKline Parkinson's Disease (PD) Drugs Product Portfolio
-
11.11.5 Recent Research and Development Strategies
-
11.12 Eli Lilly
-
11.12.1 Eli Lilly Company Details
-
11.12.2 Eli Lilly Parkinson's Disease (PD) Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
11.12.3 Eli Lilly Parkinson's Disease (PD) Drugs Main Business and Markets Served
-
11.12.4 Eli Lilly Parkinson's Disease (PD) Drugs Product Portfolio
-
11.12.5 Recent Research and Development Strategies
-
11.13 Boehringer Ingelheim
-
11.13.1 Boehringer Ingelheim Company Details
-
11.13.2 Boehringer Ingelheim Parkinson's Disease (PD) Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
11.13.3 Boehringer Ingelheim Parkinson's Disease (PD) Drugs Main Business and Markets Served
-
11.13.4 Boehringer Ingelheim Parkinson's Disease (PD) Drugs Product Portfolio
-
11.13.5 Recent Research and Development Strategies
-
11.14 Teva Pharmaceutical Industries
-
11.14.1 Teva Pharmaceutical Industries Company Details
-
11.14.2 Teva Pharmaceutical Industries Parkinson's Disease (PD) Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
11.14.3 Teva Pharmaceutical Industries Parkinson's Disease (PD) Drugs Main Business and Markets Served
-
11.14.4 Teva Pharmaceutical Industries Parkinson's Disease (PD) Drugs Product Portfolio
-
11.14.5 Recent Research and Development Strategies
-
11.15 Eisai
-
11.15.1 Eisai Company Details
-
11.15.2 Eisai Parkinson's Disease (PD) Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
11.15.3 Eisai Parkinson's Disease (PD) Drugs Main Business and Markets Served
-
11.15.4 Eisai Parkinson's Disease (PD) Drugs Product Portfolio
-
11.15.5 Recent Research and Development Strategies
-
11.16 H Lundbeck
-
11.16.1 H Lundbeck Company Details
-
11.16.2 H Lundbeck Parkinson's Disease (PD) Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
11.16.3 H Lundbeck Parkinson's Disease (PD) Drugs Main Business and Markets Served
-
11.16.4 H Lundbeck Parkinson's Disease (PD) Drugs Product Portfolio
-
11.16.5 Recent Research and Development Strategies
12 Global Parkinson's Disease (PD) Drugs Market Outlook by Types and Applications to 2028
-
12.1 Global Parkinson's Disease (PD) Drugs Consumption Forecast and Growth Rate by Type (2022-2028)
-
12.1.1 Global Dopamine Agonist Consumption Forecast and Growth Rate (2022-2028)
-
12.1.2 Global Monoamine Oxidase Inhibitors Consumption Forecast and Growth Rate (2022-2028)
-
12.1.3 Global Acetylcholinesterase Inhibitors Consumption Forecast and Growth Rate (2022-2028)
-
12.1.4 Global Glutamate Inhibitors Consumption Forecast and Growth Rate (2022-2028)
-
12.2 Global Parkinson's Disease (PD) Drugs Consumption Forecast and Growth Rate by Application (2022-2028)
-
12.2.1 Global Hospital Consumption Forecast and Growth Rate (2022-2028)
-
12.2.2 Global Family Consumption Forecast and Growth Rate (2022-2028)
13 Country-wise Parkinson's Disease (PD) Drugs Market Analysis and Outlook to 2028
-
13.1 Global Parkinson's Disease (PD) Drugs Consumption Forecast (2022-2028)
-
13.2 North America Consumption Analysis
-
13.2.1 United States Parkinson's Disease (PD) Drugs Consumption Forecast (2022-2028)
-
13.2.2 Canada Parkinson's Disease (PD) Drugs Consumption Forecast (2022-2028)
-
13.2.3 Mexico Parkinson's Disease (PD) Drugs Consumption Forecast (2022-2028)
-
13.3 Europe Consumption Analysis
-
13.3.1 Germany Parkinson's Disease (PD) Drugs Consumption Forecast (2022-2028)
-
13.3.2 UK Parkinson's Disease (PD) Drugs Consumption Forecast (2022-2028)
-
13.3.3 Spain Parkinson's Disease (PD) Drugs Consumption Forecast (2022-2028)
-
13.3.4 Belgium Parkinson's Disease (PD) Drugs Consumption Forecast (2022-2028)
-
13.3.5 France Parkinson's Disease (PD) Drugs Consumption Forecast (2022-2028)
-
13.3.6 Italy Parkinson's Disease (PD) Drugs Consumption Forecast (2022-2028)
-
13.3.7 Denmark Parkinson's Disease (PD) Drugs Consumption Forecast (2022-2028)
-
13.3.8 Finland Parkinson's Disease (PD) Drugs Consumption Forecast (2022-2028)
-
13.3.9 Norway Parkinson's Disease (PD) Drugs Consumption Forecast (2022-2028)
-
13.3.10 Sweden Parkinson's Disease (PD) Drugs Consumption Forecast (2022-2028)
-
13.3.11 Poland Parkinson's Disease (PD) Drugs Consumption Forecast (2022-2028)
-
13.3.12 Russia Parkinson's Disease (PD) Drugs Consumption Forecast (2022-2028)
-
13.3.13 Turkey Parkinson's Disease (PD) Drugs Consumption Forecast (2022-2028)
-
13.4 APAC Consumption Analysis
-
13.4.1 China Parkinson's Disease (PD) Drugs Consumption Forecast (2022-2028)
-
13.4.2 Japan Parkinson's Disease (PD) Drugs Consumption Forecast (2022-2028)
-
13.4.3 India Parkinson's Disease (PD) Drugs Consumption Forecast (2022-2028)
-
13.4.4 South Korea Parkinson's Disease (PD) Drugs Consumption Forecast (2022-2028)
-
13.4.5 Pakistan Parkinson's Disease (PD) Drugs Consumption Forecast (2022-2028)
-
13.4.6 Bangladesh Parkinson's Disease (PD) Drugs Consumption Forecast (2022-2028)
-
13.4.7 Indonesia Parkinson's Disease (PD) Drugs Consumption Forecast (2022-2028)
-
13.4.8 Thailand Parkinson's Disease (PD) Drugs Consumption Forecast (2022-2028)
-
13.4.9 Singapore Parkinson's Disease (PD) Drugs Consumption Forecast (2022-2028)
-
13.4.10 Malaysia Parkinson's Disease (PD) Drugs Consumption Forecast (2022-2028)
-
13.4.11 Philippines Parkinson's Disease (PD) Drugs Consumption Forecast (2022-2028)
-
13.4.12 Vietnam Parkinson's Disease (PD) Drugs Consumption Forecast (2022-2028)
-
13.5 South America Consumption Analysis
-
13.5.1 Brazil Parkinson's Disease (PD) Drugs Consumption Forecast (2022-2028)
-
13.5.2 Colombia Parkinson's Disease (PD) Drugs Consumption Forecast (2022-2028)
-
13.5.3 Chile Parkinson's Disease (PD) Drugs Consumption Forecast (2022-2028)
-
13.5.4 Argentina Parkinson's Disease (PD) Drugs Consumption Forecast (2022-2028)
-
13.5.5 Venezuela Parkinson's Disease (PD) Drugs Consumption Forecast (2022-2028)
-
13.5.6 Peru Parkinson's Disease (PD) Drugs Consumption Forecast (2022-2028)
-
13.5.7 Puerto Rico Parkinson's Disease (PD) Drugs Consumption Forecast (2022-2028)
-
13.5.8 Ecuador Parkinson's Disease (PD) Drugs Consumption Forecast (2022-2028)
-
13.6 GCC Consumption Analysis
-
13.6.1 Bahrain Parkinson's Disease (PD) Drugs Consumption Forecast (2022-2028)
-
13.6.2 Kuwait Parkinson's Disease (PD) Drugs Consumption Forecast (2022-2028)
-
13.6.3 Oman Parkinson's Disease (PD) Drugs Consumption Forecast (2022-2028)
-
13.6.4 Qatar Parkinson's Disease (PD) Drugs Consumption Forecast (2022-2028)
-
13.6.5 Saudi Arabia Parkinson's Disease (PD) Drugs Consumption Forecast (2022-2028)
-
13.6.6 United Arab Emirates Parkinson's Disease (PD) Drugs Consumption Forecast (2022-2028)
-
13.7 Africa Consumption Analysis
-
13.7.1 Nigeria Parkinson's Disease (PD) Drugs Consumption Forecast (2022-2028)
-
13.7.2 South Africa Parkinson's Disease (PD) Drugs Consumption Forecast (2022-2028)
-
13.7.3 Egypt Parkinson's Disease (PD) Drugs Consumption Forecast (2022-2028)
-
13.7.4 Algeria Parkinson's Disease (PD) Drugs Consumption Forecast (2022-2028)
-
13.8 Oceania Consumption Analysis
-
13.8.1 Australia Parkinson's Disease (PD) Drugs Consumption Forecast (2022-2028)
-
13.8.2 New Zealand Parkinson's Disease (PD) Drugs Consumption Forecast (2022-2028)
14 Conclusions
The List of Tables and Figures
-
Table Definition of Parkinson's Disease (PD) Drugs
-
Figure of Parkinson's Disease (PD) Drugs Picture
-
Table Global Parkinson's Disease (PD) Drugs Import by Region (Top 10 Countries) (2017-2028)
-
Table Global Parkinson's Disease (PD) Drugs Export by Region (Top 10 Countries) (2017-2028)
-
Figure Global Dopamine Agonist Consumption and Growth Rate (2017-2022)
-
Figure Global Monoamine Oxidase Inhibitors Consumption and Growth Rate (2017-2022)
-
Figure Global Acetylcholinesterase Inhibitors Consumption and Growth Rate (2017-2022)
-
Figure Global Glutamate Inhibitors Consumption and Growth Rate (2017-2022)
-
Figure Global Hospital Consumption and Growth Rate (2017-2022)
-
Figure Global Family Consumption and Growth Rate (2017-2022)
-
Figure Global Parkinson's Disease (PD) Drugs Consumption by Country (2017-2022)
-
Table North America Parkinson's Disease (PD) Drugs Consumption by Country (2017-2022)
-
Figure United States Parkinson's Disease (PD) Drugs Consumption and Growth Rate (2017-2022)
-
Figure Canada Parkinson's Disease (PD) Drugs Consumption and Growth Rate (2017-2022)
-
Figure Mexico Parkinson's Disease (PD) Drugs Consumption and Growth Rate (2017-2022)
-
Table Europe Parkinson's Disease (PD) Drugs Consumption by Country (2017-2022)
-
Figure Germany Parkinson's Disease (PD) Drugs Consumption and Growth Rate (2017-2022)
-
Figure UK Parkinson's Disease (PD) Drugs Consumption and Growth Rate (2017-2022)
-
Figure Spain Parkinson's Disease (PD) Drugs Consumption and Growth Rate (2017-2022)
-
Figure Belgium Parkinson's Disease (PD) Drugs Consumption and Growth Rate (2017-2022)
-
Figure France Parkinson's Disease (PD) Drugs Consumption and Growth Rate (2017-2022)
-
Figure Italy Parkinson's Disease (PD) Drugs Consumption and Growth Rate (2017-2022)
-
Figure Denmark Parkinson's Disease (PD) Drugs Consumption and Growth Rate (2017-2022)
-
Figure Finland Parkinson's Disease (PD) Drugs Consumption and Growth Rate (2017-2022)
-
Figure Norway Parkinson's Disease (PD) Drugs Consumption and Growth Rate (2017-2022)
-
Figure Sweden Parkinson's Disease (PD) Drugs Consumption and Growth Rate (2017-2022)
-
Figure Poland Parkinson's Disease (PD) Drugs Consumption and Growth Rate (2017-2022)
-
Figure Russia Parkinson's Disease (PD) Drugs Consumption and Growth Rate (2017-2022)
-
Figure Turkey Parkinson's Disease (PD) Drugs Consumption and Growth Rate (2017-2022)
-
Table APAC Parkinson's Disease (PD) Drugs Consumption by Country (2017-2022)
-
Figure China Parkinson's Disease (PD) Drugs Consumption and Growth Rate (2017-2022)
-
Figure Japan Parkinson's Disease (PD) Drugs Consumption and Growth Rate (2017-2022)
-
Figure India Parkinson's Disease (PD) Drugs Consumption and Growth Rate (2017-2022)
-
Figure South Korea Parkinson's Disease (PD) Drugs Consumption and Growth Rate (2017-2022)
-
Figure Pakistan Parkinson's Disease (PD) Drugs Consumption and Growth Rate (2017-2022)
-
Figure Bangladesh Parkinson's Disease (PD) Drugs Consumption and Growth Rate (2017-2022)
-
Figure Indonesia Parkinson's Disease (PD) Drugs Consumption and Growth Rate (2017-2022)
-
Figure Thailand Parkinson's Disease (PD) Drugs Consumption and Growth Rate (2017-2022)
-
Figure Singapore Parkinson's Disease (PD) Drugs Consumption and Growth Rate (2017-2022)
-
Figure Malaysia Parkinson's Disease (PD) Drugs Consumption and Growth Rate (2017-2022)
-
Figure Philippines Parkinson's Disease (PD) Drugs Consumption and Growth Rate (2017-2022)
-
Figure Vietnam Parkinson's Disease (PD) Drugs Consumption and Growth Rate (2017-2022)
-
Table South America Parkinson's Disease (PD) Drugs Consumption by Country (2017-2022)
-
Figure Brazil Parkinson's Disease (PD) Drugs Consumption and Growth Rate (2017-2022)
-
Figure Colombia Parkinson's Disease (PD) Drugs Consumption and Growth Rate (2017-2022)
-
Figure Chile Parkinson's Disease (PD) Drugs Consumption and Growth Rate (2017-2022)
-
Figure Argentina Parkinson's Disease (PD) Drugs Consumption and Growth Rate (2017-2022)
-
Figure Venezuela Parkinson's Disease (PD) Drugs Consumption and Growth Rate (2017-2022)
-
Figure Peru Parkinson's Disease (PD) Drugs Consumption and Growth Rate (2017-2022)
-
Figure Puerto Rico Parkinson's Disease (PD) Drugs Consumption and Growth Rate (2017-2022)
-
Figure Ecuador Parkinson's Disease (PD) Drugs Consumption and Growth Rate (2017-2022)
-
Table GCC Parkinson's Disease (PD) Drugs Consumption by Country (2017-2022)
-
Figure Bahrain Parkinson's Disease (PD) Drugs Consumption and Growth Rate (2017-2022)
-
Figure Kuwait Parkinson's Disease (PD) Drugs Consumption and Growth Rate (2017-2022)
-
Figure Oman Parkinson's Disease (PD) Drugs Consumption and Growth Rate (2017-2022)
-
Figure Qatar Parkinson's Disease (PD) Drugs Consumption and Growth Rate (2017-2022)
-
Figure Saudi Arabia Parkinson's Disease (PD) Drugs Consumption and Growth Rate (2017-2022)
-
Figure United Arab Emirates Parkinson's Disease (PD) Drugs Consumption and Growth Rate (2017-2022)
-
Table Africa Parkinson's Disease (PD) Drugs Consumption by Country (2017-2022)
-
Figure Nigeria Parkinson's Disease (PD) Drugs Consumption and Growth Rate (2017-2022)
-
Figure South Africa Parkinson's Disease (PD) Drugs Consumption and Growth Rate (2017-2022)
-
Figure Egypt Parkinson's Disease (PD) Drugs Consumption and Growth Rate (2017-2022)
-
Figure Algeria Parkinson's Disease (PD) Drugs Consumption and Growth Rate (2017-2022)
-
Table Oceania Parkinson's Disease (PD) Drugs Consumption by Country (2017-2022)
-
Figure Australia Parkinson's Disease (PD) Drugs Consumption and Growth Rate (2017-2022)
-
Figure New Zealand Parkinson's Disease (PD) Drugs Consumption and Growth Rate (2017-2022)
-
Table AbbVie Company Details
-
Table AbbVie Parkinson's Disease (PD) Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table AbbVie Parkinson's Disease (PD) Drugs Main Business and Markets Served
-
Table AbbVie Parkinson's Disease (PD) Drugs Product Portfolio
-
Table Pfizer Company Details
-
Table Pfizer Parkinson's Disease (PD) Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table Pfizer Parkinson's Disease (PD) Drugs Main Business and Markets Served
-
Table Pfizer Parkinson's Disease (PD) Drugs Product Portfolio
-
Table Otsuka Pharmaceutical Company Details
-
Table Otsuka Pharmaceutical Parkinson's Disease (PD) Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table Otsuka Pharmaceutical Parkinson's Disease (PD) Drugs Main Business and Markets Served
-
Table Otsuka Pharmaceutical Parkinson's Disease (PD) Drugs Product Portfolio
-
Table Biogen Company Details
-
Table Biogen Parkinson's Disease (PD) Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table Biogen Parkinson's Disease (PD) Drugs Main Business and Markets Served
-
Table Biogen Parkinson's Disease (PD) Drugs Product Portfolio
-
Table F Hoffmann-La Roche Company Details
-
Table F Hoffmann-La Roche Parkinson's Disease (PD) Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table F Hoffmann-La Roche Parkinson's Disease (PD) Drugs Main Business and Markets Served
-
Table F Hoffmann-La Roche Parkinson's Disease (PD) Drugs Product Portfolio
-
Table Kyowa Hakko Kirin Company Details
-
Table Kyowa Hakko Kirin Parkinson's Disease (PD) Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table Kyowa Hakko Kirin Parkinson's Disease (PD) Drugs Main Business and Markets Served
-
Table Kyowa Hakko Kirin Parkinson's Disease (PD) Drugs Product Portfolio
-
Table Impax Laboratories Company Details
-
Table Impax Laboratories Parkinson's Disease (PD) Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table Impax Laboratories Parkinson's Disease (PD) Drugs Main Business and Markets Served
-
Table Impax Laboratories Parkinson's Disease (PD) Drugs Product Portfolio
-
Table Novartis Company Details
-
Table Novartis Parkinson's Disease (PD) Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table Novartis Parkinson's Disease (PD) Drugs Main Business and Markets Served
-
Table Novartis Parkinson's Disease (PD) Drugs Product Portfolio
-
Table Addex Therapeutics Company Details
-
Table Addex Therapeutics Parkinson's Disease (PD) Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table Addex Therapeutics Parkinson's Disease (PD) Drugs Main Business and Markets Served
-
Table Addex Therapeutics Parkinson's Disease (PD) Drugs Product Portfolio
-
Table Abital Pharma Company Details
-
Table Abital Pharma Parkinson's Disease (PD) Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table Abital Pharma Parkinson's Disease (PD) Drugs Main Business and Markets Served
-
Table Abital Pharma Parkinson's Disease (PD) Drugs Product Portfolio
-
Table GlaxoSmithKline Company Details
-
Table GlaxoSmithKline Parkinson's Disease (PD) Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table GlaxoSmithKline Parkinson's Disease (PD) Drugs Main Business and Markets Served
-
Table GlaxoSmithKline Parkinson's Disease (PD) Drugs Product Portfolio
-
Table Eli Lilly Company Details
-
Table Eli Lilly Parkinson's Disease (PD) Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table Eli Lilly Parkinson's Disease (PD) Drugs Main Business and Markets Served
-
Table Eli Lilly Parkinson's Disease (PD) Drugs Product Portfolio
-
Table Boehringer Ingelheim Company Details
-
Table Boehringer Ingelheim Parkinson's Disease (PD) Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table Boehringer Ingelheim Parkinson's Disease (PD) Drugs Main Business and Markets Served
-
Table Boehringer Ingelheim Parkinson's Disease (PD) Drugs Product Portfolio
-
Table Teva Pharmaceutical Industries Company Details
-
Table Teva Pharmaceutical Industries Parkinson's Disease (PD) Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table Teva Pharmaceutical Industries Parkinson's Disease (PD) Drugs Main Business and Markets Served
-
Table Teva Pharmaceutical Industries Parkinson's Disease (PD) Drugs Product Portfolio
-
Table Eisai Company Details
-
Table Eisai Parkinson's Disease (PD) Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table Eisai Parkinson's Disease (PD) Drugs Main Business and Markets Served
-
Table Eisai Parkinson's Disease (PD) Drugs Product Portfolio
-
Table H Lundbeck Company Details
-
Table H Lundbeck Parkinson's Disease (PD) Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table H Lundbeck Parkinson's Disease (PD) Drugs Main Business and Markets Served
-
Table H Lundbeck Parkinson's Disease (PD) Drugs Product Portfolio
-
Figure Global Dopamine Agonist Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Monoamine Oxidase Inhibitors Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Acetylcholinesterase Inhibitors Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Glutamate Inhibitors Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Hospital Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Family Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Parkinson's Disease (PD) Drugs Consumption Forecast by Country (2022-2028)
-
Table North America Parkinson's Disease (PD) Drugs Consumption Forecast by Country (2022-2028)
-
Figure United States Parkinson's Disease (PD) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Canada Parkinson's Disease (PD) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Mexico Parkinson's Disease (PD) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Table Europe Parkinson's Disease (PD) Drugs Consumption Forecast by Country (2022-2028)
-
Figure Germany Parkinson's Disease (PD) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure UK Parkinson's Disease (PD) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Spain Parkinson's Disease (PD) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Belgium Parkinson's Disease (PD) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure France Parkinson's Disease (PD) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Italy Parkinson's Disease (PD) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Denmark Parkinson's Disease (PD) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Finland Parkinson's Disease (PD) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Norway Parkinson's Disease (PD) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Sweden Parkinson's Disease (PD) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Poland Parkinson's Disease (PD) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Russia Parkinson's Disease (PD) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Turkey Parkinson's Disease (PD) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Table APAC Parkinson's Disease (PD) Drugs Consumption Forecast by Country (2022-2028)
-
Figure China Parkinson's Disease (PD) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Japan Parkinson's Disease (PD) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure India Parkinson's Disease (PD) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure South Korea Parkinson's Disease (PD) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Pakistan Parkinson's Disease (PD) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Bangladesh Parkinson's Disease (PD) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Indonesia Parkinson's Disease (PD) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Thailand Parkinson's Disease (PD) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Singapore Parkinson's Disease (PD) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Malaysia Parkinson's Disease (PD) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Philippines Parkinson's Disease (PD) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Vietnam Parkinson's Disease (PD) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Table South America Parkinson's Disease (PD) Drugs Consumption Forecast by Country (2022-2028)
-
Figure Brazil Parkinson's Disease (PD) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Colombia Parkinson's Disease (PD) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Chile Parkinson's Disease (PD) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Argentina Parkinson's Disease (PD) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Venezuela Parkinson's Disease (PD) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Peru Parkinson's Disease (PD) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Puerto Rico Parkinson's Disease (PD) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Ecuador Parkinson's Disease (PD) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Table GCC Parkinson's Disease (PD) Drugs Consumption Forecast by Country (2022-2028)
-
Figure Bahrain Parkinson's Disease (PD) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Kuwait Parkinson's Disease (PD) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Oman Parkinson's Disease (PD) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Qatar Parkinson's Disease (PD) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Saudi Arabia Parkinson's Disease (PD) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure United Arab Emirates Parkinson's Disease (PD) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Table Africa Parkinson's Disease (PD) Drugs Consumption Forecast by Country (2022-2028)
-
Figure Nigeria Parkinson's Disease (PD) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure South Africa Parkinson's Disease (PD) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Egypt Parkinson's Disease (PD) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Algeria Parkinson's Disease (PD) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Table Oceania Parkinson's Disease (PD) Drugs Consumption Forecast by Country (2022-2028)
-
Figure Australia Parkinson's Disease (PD) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure New Zealand Parkinson's Disease (PD) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
